- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12
- On Track for Release of Topline Results in Third Quarter of 2018
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2017.
“As VTL-308 nears completion, I am proud of the job our team has done in designing and running this pivotal trial,” said Russell J. Cox, the Company’s Chief Executive Officer. “Not only do baseline characteristics of subjects continue to track closely to the reference population, but also, blended event rates were found to be consistent with our modeled expectations. We look forward to reporting topline results in the third quarter, and in the event of a positive outcome, preparing to file a biologics license application next year.”
Key Recent Developments
|Data||Age (years)||MELD||Bilirubin (mg/dL)||INR||Creatinine|
|VTL-308 enrollment limits||<50 yrs||<30||≥16 mg/dL||≤2.5||<1.3mg/dL|
|VTI-208 reference population|
|Mean (range)||40.10 |
(28 - 49)
(20 - 29)
(16.6 - 52.6)
(1.0 - 2.5)
(0.10 - 1.30)
(23 - 49)
(19 - 29)
(16.0 – 44.7)
(0.95 – 2.50)
(0.30 - 1.27)
Fourth Quarter 2017 Financial Results
Cash and cash equivalents at December 31, 2017, totaled $56.9 million compared to $60.0 million at December 31, 2016. The Company believes its current cash position should provide funding through the first quarter of 2019, well past the expected announcement of VTL-308 top-line trial results.
Results of Operations
Three Months Ended December 31, 2017
The Company reported a net loss of $14.6 million for the three months ended December 31, 2017, which compared with a net loss of $11.7 million for the same prior year period. This resulted in a net loss of $0.35 per share for the three months ended December 31, 2017, as compared to a net loss of $0.37 per share for the corresponding period in 2016, on both a basic and diluted basis. These per share figures are based on weighted-average common shares outstanding of 42,244,880 shares and 32,083,830 shares, respectively, with the increase in common shares outstanding at December 31, 2017 primarily attributable to shares issued as part of the Company’s follow-on offering in the first quarter of 2017.
Research and development expenses increased to $10.2 million for the three months ended December 31, 2017 as compared to $8.9 million for the three months ended December 31, 2016. This was primarily due to an increase in clinical trial and related costs in comparison to the prior year period. General and administrative expenses were $4.6 million for the three months ended December 31, 2017, as compared to $3.0 million for the three months ended December 31, 2016.
Upcoming Investor Conference
The Company will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10th at 3:50 PM Central European Time (10:50 AM Eastern). A live webcast of the Company's presentation will be available on the Investor Relations page of the Company's website at: http://it.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
Conference Call Details
Vital Therapies will host a conference call to discuss these results and provide a corporate update today at 4:30 PM ET, which will be open to the public. The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 7392256. Participants can access the live webcast via a link on the Vital Therapies website in the Investor Relations section under “Events” at: http://ir.vitaltherapies.com/.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 7392256.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying the timing and conduct of our clinical trials and the timing of the release of the results from these trials, and statements regarding our projected cash runway. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
Risks and uncertainties include, but are not limited to, difficulty maintaining regulatory approvals in the United States or Europe, in particular for a combination product and open-label clinical trials; our limited experience in conducting pivotal clinical trials and significant issues regarding our clinical trials, including, but not limited to, clinical sites’ continued adherence to protocols; assumptions regarding the number of subjects to be enrolled, enrollment rates, and the timing of subjects meeting inclusion and exclusion criteria; changes to protocols or regulatory requirements; the need to comply with and meet applicable laws and regulations; and unexpected adverse events or safety issues; event rates may vary from projections, and the use of cash can vary based on the timing of incurring costs for activities to support our clinical trial and any applications for marketing approval, and whether or when we begin building any significant commercial infrastructure. There can be no assurance that data from any of our clinical trials will be sufficient to support an application for marketing in any country or that any such application will ever be approved.
These and other risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Annual Report on Form 10-K for the year ended December 31, 2017. These forward-looking statements speak only as of the date hereof, and Vital Therapies, Inc. disclaims any obligation to update these statements except as may be required by law.
Vital Therapies, Inc.
Vice President, Investor Relations and Business Development
|Vital Therapies, Inc.|
|Condensed Consolidated Balance Sheets|
|(unaudited, in thousands)|
|Cash and cash equivalents||$||56,901||$||59,991|
|Other current assets and prepaid expenses||1,220||1,472|
|Property and equipment, net||2,155||2,505|
|Accounts payable, accrued expenses and other current liabilities||$||10,281||$||5,480|
|Total liabilities and stockholders' equity||$||60,384||$||64,026|
|Vital Therapies, Inc.|
|Condensed Consolidated Statements of Operations|
|(unaudited and in thousands, except per share data)|
|Ended December 31,||Ended December 31,|
|Research and development||$||10,190||$||8,862||$||39,341||$||30,046|
|General and administrative||4,590||2,963||13,314||11,220|
|Total operating expenses||14,780||11,825||52,655||41,266|
|Loss from operations||(14,780||)||(11,825||)||(52,655||)||(41,266||)|
|Net loss per share, basic and diluted||$||(0.35||)||$||(0.37||)||$||(1.31||)||$||(1.31||)|
|Weighted-average common shares|
|outstanding, basic and diluted||42,244,880||32,083,830||39,859,009||31,387,579|